Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free ORMP Stock Alerts

Oramed Pharmaceuticals (ORMP) Financials

Oramed Pharmaceuticals logo
$4.04 -0.14 (-3.35%)
Closing price 04:00 PM Eastern
Extended Trading
$4.07 +0.03 (+0.62%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Oramed Pharmaceuticals

Annual Income Statements for Oramed Pharmaceuticals

This table shows Oramed Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.23 -11 -10 -13 -14 -12 -22 -37 4.65 -19 64
Consolidated Net Income / (Loss)		 -7.23 -11 -10 -13 -14 -12 -23 -38 11 -19 64
Net Income / (Loss) Continuing Operations		 -7.23 -11 -10 -13 -14 -12 -23 -38 5.09 -19 64
Total Pre-Tax Income 		-7.23 -9.63 -10 -13 -14 -12 -23 -38 5.09 -16 75
Total Operating Income		 -7.38 -10 -11 -14 -15 -12 -24 -41 -16 -13 -15
Total Gross Profit		 0.00 0.64 2.27 2.54 2.61 2.71 2.70 0.85 1.63 0.00 0.01
Total Revenue		 0.00 0.64 2.46 2.45 2.70 2.71 2.70 0.85 1.63 0.00 2.00
Operating Revenue		 0.00 0.64 2.46 2.45 2.70 2.71 2.70 0.85 1.63 0.00 2.00
Total Cost of Revenue		 0.00 0.00 0.19 -0.09 0.09 0.00 0.00 0.00 0.00 0.00 1.99
Operating Cost of Revenue		 0.00 - 0.19 -0.09 0.09 - - - - 0.00 1.99
Total Operating Expenses		 7.38 11 13 16 17 14 27 41 17 13 15
Selling, General & Admin Expense		 2.60 2.45 2.76 4.08 3.72 4.23 5.94 14 8.43 6.46 8.72
Research & Development Expense		 4.78 7.71 10 12 14 10 21 28 8.97 6.32 6.38
Total Other Income / (Expense), net		 0.15 0.38 0.69 0.80 0.58 0.25 1.23 2.93 21 -3.14 90
Interest Expense		 - - - - - - - 0.00 2.04 0.85 0.00
Other Income / (Expense), net		 - - - - 0.58 -0.44 -0.01 2.93 23 -2.29 90
Income Tax Expense		 -0.00 1.34 0.40 0.00 0.30 - - 0.10 0.00 3.18 11
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - 0.00 -0.75 -1.20 0.44 -0.04 -0.03
Basic Earnings per Share		 $0.67 $0.87 - - $0.82 $0.56 $0.78 ($0.94) $0.14 ($0.48) $1.53
Weighted Average Basic Shares Outstanding		 10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 38.09M 39.00M 40.32M 40.85M 41.40M
Diluted Earnings per Share		 $0.67 $0.87 - - $0.82 $0.56 $0.78 ($0.94) $0.14 ($0.48) $1.50
Weighted Average Diluted Shares Outstanding		 10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 38.09M 39.00M 40.57M 40.85M 42.42M
Weighted Average Basic & Diluted Shares Outstanding		 10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 28.47M 39.78M 40.52M 40.85M 40.45M
Cash Dividends to Common per Share		 - - - - - - - - - - $0.25

Quarterly Income Statements for Oramed Pharmaceuticals

This table shows Oramed Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.22 12 1.54 9.21 -20 -10 -7.64 13 48 10 38
Consolidated Net Income / (Loss)		 -3.28 19 1.53 9.20 -20 -10 -7.64 13 48 10 38
Net Income / (Loss) Continuing Operations		 -3.28 13 1.53 9.20 -20 -10 -7.64 13 48 10 38
Total Pre-Tax Income 		-3.28 13 1.53 11 -19 -9.78 -7.06 13 59 9.80 49
Total Operating Income		 -2.89 -3.88 -2.96 -3.14 -3.09 -3.60 -4.50 -2.49 -2.43 -5.67 -3.66
Total Gross Profit		 0.66 -0.38 0.00 0.00 0.00 - 0.01 0.00 0.00 - 0.00
Total Revenue		 0.66 -0.38 0.00 0.00 0.00 - 2.00 0.00 0.00 - 0.00
Operating Revenue		 0.66 -0.38 0.00 0.00 0.00 - 2.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 1.99 0.00 0.00 - 0.00
Operating Cost of Revenue		 - - 0.00 0.00 0.00 - 1.99 0.00 0.00 - 0.00
Total Operating Expenses		 3.56 3.50 2.96 3.14 3.09 3.60 4.51 2.49 2.43 5.67 3.66
Selling, General & Admin Expense		 2.60 2.11 1.78 1.69 0.85 2.13 2.31 1.46 1.27 3.68 2.07
Research & Development Expense		 0.96 1.77 1.18 1.44 2.24 1.46 2.21 1.03 1.15 1.99 1.59
Total Other Income / (Expense), net		 -0.39 17 4.50 14 -15 -6.19 -2.56 16 62 15 53
Other Income / (Expense), net		 0.44 18 5.09 14 -15 -6.19 -2.56 16 62 15 53
Income Tax Expense		 0.00 - 0.00 1.63 1.13 0.42 0.58 -0.13 11 -0.21 11
Basic Earnings per Share		 ($0.08) $0.33 $0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.32 $1.16 $0.24 $0.94
Weighted Average Basic Shares Outstanding		 40.45M 40.32M 40.84M 40.96M 40.90M 40.85M 41.23M 41.74M 41.76M 41.40M 40.77M
Diluted Earnings per Share		 ($0.08) $0.33 $0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.31 $1.13 $0.25 $0.91
Weighted Average Diluted Shares Outstanding		 40.45M 40.57M 41.56M 41.59M 40.90M 40.85M 41.23M 42.61M 42.77M 42.42M 41.97M
Weighted Average Basic & Diluted Shares Outstanding		 40.34M 40.52M 40.63M 40.77M 40.31M 0.00 40.85M 41.00M 39.80M 0.00 40.93M

Annual Cash Flow Statements for Oramed Pharmaceuticals

This table details how cash moves in and out of Oramed Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.45 0.69 0.06 1.03 -1.67 16 58 13 -31 45 -8.47
Net Cash From Operating Activities		 -4.95 4.66 -5.83 -15 -13 -12 -21 -28 -10 -8.41 -9.15
Net Cash From Continuing Operating Activities		 -4.95 4.66 -5.83 -15 -13 -12 -21 -28 -10 -8.41 -9.15
Net Income / (Loss) Continuing Operations		 -7.23 -11 -10 -13 -14 -12 -23 -38 5.09 -19 64
Consolidated Net Income / (Loss)		 -7.23 -11 -10 -13 -14 -12 -23 -38 5.09 -19 64
Depreciation Expense		 0.00 0.00 0.01 0.01 0.01 0.01 0.08 0.06 0.20 0.19 0.12
Non-Cash Adjustments To Reconcile Net Income		 1.77 0.57 1.77 1.67 1.12 2.22 3.05 11 -13 7.34 -79
Changes in Operating Assets and Liabilities, net		 0.52 15 2.87 -3.60 0.29 -3.16 -1.32 -0.94 -2.70 3.16 5.89
Net Cash From Investing Activities		 -3.31 -16 4.30 -7.00 11 4.63 -24 30 -73 106 5.44
Net Cash From Continuing Investing Activities		 -3.31 -16 4.30 -7.00 11 4.63 -24 30 -73 106 5.44
Purchase of Property, Plant & Equipment		 -0.00 -0.01 -0.01 -0.01 -0.02 -0.08 -0.38 -0.50 -0.25 -0.02 -0.01
Acquisitions		 - - - - - - - - - 0.00 -7.00
Purchase of Investments		 -23 -31 -25 -27 -31 -36 -54 -154 -191 -54 -23
Divestitures		 - - - - - - - - - 0.00 6.25
Sale and/or Maturity of Investments		 20 15 29 20 42 44 27 185 8.38 162 97
Other Investing Activities, net		 -0.00 -0.00 -0.00 -0.00 -0.00 -3.75 3.76 0.00 110 -1.37 -68
Net Cash From Financing Activities		 9.72 12 1.59 23 0.00 24 103 11 52 -52 -4.74
Net Cash From Continuing Financing Activities		 9.72 12 1.59 23 0.00 24 103 11 52 -52 -4.74
Repayment of Debt		 - - - - - - - 0.00 -50 -50 0.00
Repurchase of Common Equity		 - - - - - - - - 0.00 -2.48 -4.74
Other Financing Activities, net		 0.01 1.45 1.59 23 0.00 0.01 21 -0.72 0.00 -0.00 0.00
Cash Interest Received		 0.12 0.26 0.83 0.83 - 1.31 - 1.84 5.16 7.38 4.63
Cash Income Taxes Paid		 - - 0.40 0.00 0.30 - 0.56 0.10 - 2.32 0.00

Quarterly Cash Flow Statements for Oramed Pharmaceuticals

This table details how cash moves in and out of Oramed Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.30 3.59 9.52 66 -43 12 20 -59 36 -6.19 -33
Net Cash From Operating Activities		 -0.69 -1.42 -1.48 2.08 -7.10 -1.91 -3.52 -3.54 -1.63 -0.47 -2.92
Net Cash From Continuing Operating Activities		 -0.69 -1.42 -1.48 2.08 -7.10 -1.91 -3.65 -3.54 -1.63 -0.47 -2.92
Net Income / (Loss) Continuing Operations		 -3.28 13 1.53 9.20 -20 -10 -7.64 13 48 10 38
Consolidated Net Income / (Loss)		 -3.28 13 1.53 9.20 -20 -10 -7.64 13 48 10 38
Depreciation Expense		 0.05 0.05 0.06 0.05 0.05 0.03 0.03 0.03 0.03 0.03 0.03
Non-Cash Adjustments To Reconcile Net Income		 0.68 -14 -2.44 -9.36 11 8.29 5.54 -14 -60 -11 -49
Changes in Operating Assets and Liabilities, net		 1.85 -0.49 -0.63 2.18 1.63 -0.03 -1.58 -2.64 9.49 0.61 7.82
Net Cash From Investing Activities		 -75 30 30 95 -34 15 24 -55 38 -1.68 -19
Net Cash From Continuing Investing Activities		 -75 30 30 95 -34 15 24 -55 38 -1.68 -7.56
Purchase of Property, Plant & Equipment		 -0.03 -0.00 -0.00 - -0.01 -0.01 -0.00 -0.00 - -0.00 -0.01
Acquisitions		 - - 0.00 - - - -7.00 -6.75 - - 0.00
Purchase of Investments		 -101 - -4.00 - -38 -12 -1.19 6.25 -1.68 -19 -13
Divestitures		 - - - - - - 2.74 - 2.81 - 0.00
Sale and/or Maturity of Investments		 0.65 5.00 15 114 5.50 28 29 8.77 38 21 6.30
Other Investing Activities, net		 25 25 19 -19 -1.31 -0.07 - -67 -0.75 -3.40 -1.00
Net Cash From Financing Activities		 75 -25 -19 -31 -1.29 -1.20 0.00 -0.37 -0.36 -4.01 -10
Net Cash From Continuing Financing Activities		 75 -25 -19 -31 -1.29 -1.20 0.00 -0.37 -0.36 -4.01 -10
Payment of Dividends		 - - - - - - 0.00 - - - -10
Cash Interest Received		 -0.53 8.55 1.34 5.10 0.43 0.50 1.18 0.17 1.08 2.19 0.40

Annual Balance Sheets for Oramed Pharmaceuticals

This table presents Oramed Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 26 43 39 47 35 45 178 162 221 155 231
Total Current Assets		 17 31 20 31 33 41 148 157 163 143 133
Cash & Equivalents		 3.21 3.91 3.97 5.00 3.33 19 27 40 9.06 54 46
Short-Term Investments		 2.09 2.86 2.86 4.59 3.70 9.54 7.75 3.74 58 32 69
Inventories, net		 - - - - - - - - - - 4.64
Prepaid Expenses		 0.13 0.20 0.16 0.57 1.04 0.61 1.66 1.39 0.54 1.29 2.74
Other Current Assets		 12 24 13 21 25 11 111 112 95 55 11
Plant, Property, & Equipment, net		 0.01 0.02 0.02 0.02 0.02 0.10 0.39 0.82 0.87 0.70 0.59
Total Noncurrent Assets		 8.97 12 18 16 1.32 4.02 29 3.72 57 11 97
Long-Term Investments		 8.96 12 18 16 1.30 3.93 29 2.70 56 11 82
Other Noncurrent Operating Assets		 - 0.01 0.01 0.02 0.02 0.09 0.53 1.02 0.73 0.45 15
Total Liabilities & Shareholders' Equity		 26 43 39 47 35 45 178 162 221 155 231
Total Liabilities		 1.53 17 19 16 15 12 11 10 58 9.93 31
Total Current Liabilities		 1.49 3.62 5.17 4.55 5.31 4.54 7.37 5.75 53 5.69 19
Short-Term Debt		 - - - - - 0.09 0.00 0.00 51 0.33 0.65
Accounts Payable		 0.99 1.46 2.72 2.10 2.61 1.70 4.54 4.16 1.61 5.14 6.20
Dividends Payable		 - - - - - - - - - 0.00 11
Current Deferred Revenue		 0.50 2.16 2.45 2.45 2.70 2.70 2.70 1.34 - 0.00 1.35
Other Current Liabilities		 - - - - 0.00 0.04 0.13 0.25 0.27 0.22 0.29
Total Noncurrent Liabilities		 0.04 13 14 12 9.96 7.22 3.84 4.74 4.44 4.25 12
Noncurrent Deferred Revenue		 0.00 13 14 11 9.66 - 3.34 4.00 4.00 4.00 3.27
Noncurrent Deferred & Payable Income Tax Liabilities		 0.03 0.01 0.01 0.01 0.01 0.01 0.01 - 0.01 0.00 7.91
Noncurrent Employee Benefit Liabilities		 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.04
Other Noncurrent Operating Liabilities		 0.00 0.39 0.44 0.31 0.27 0.24 0.47 0.72 0.41 0.22 0.54
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 25 26 19 31 19 33 167 151 163 145 200
Total Preferred & Common Equity		 25 26 19 31 19 33 166 152 164 146 200
Total Common Equity		 25 26 19 31 19 33 166 152 164 146 200
Common Stock		 59 72 75 100 100 125 293 315 321 323 323
Retained Earnings		 -35 -46 -56 -69 -81 -93 -127 -163 -158 -177 -123

Quarterly Balance Sheets for Oramed Pharmaceuticals

This table presents Oramed Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 231 204 184 165 148 162 220 269
Total Current Assets		 176 177 153 143 131 99 136 68
Cash & Equivalents		 5.47 19 85 42 75 16 52 13
Short-Term Investments		 49 78 66 57 29 59 78 42
Inventories, net		 - - - - - - - 0.00
Prepaid Expenses		 0.67 0.50 0.53 0.47 0.83 1.09 1.43 2.31
Other Current Assets		 120 80 1.78 43 27 23 4.04 11
Plant, Property, & Equipment, net		 0.92 0.82 0.77 0.72 0.67 0.65 0.61 0.56
Total Noncurrent Assets		 54 26 30 22 14 62 84 200
Long-Term Investments		 53 25 2.35 21 9.53 59 82 145
Other Noncurrent Operating Assets		 0.77 0.64 28 0.52 4.64 3.45 1.90 55
Total Liabilities & Shareholders' Equity		 231 204 184 165 148 162 220 269
Total Liabilities		 83 38 8.07 9.56 7.65 8.10 18 31
Total Current Liabilities		 78 34 3.73 5.27 5.49 3.69 6.12 11
Short-Term Debt		 75 32 0.00 0.04 0.04 0.03 0.00 0.00
Accounts Payable		 2.56 1.27 3.48 5.00 5.28 2.16 4.86 8.52
Dividends Payable		 - - - - - - - 0.50
Current Deferred Revenue		 0.00 - - - - 1.24 0.99 1.47
Other Current Liabilities		 0.25 0.25 0.25 0.24 0.18 0.26 0.27 0.27
Total Noncurrent Liabilities		 4.46 4.38 4.34 4.29 2.15 4.41 12 20
Noncurrent Deferred Revenue		 4.00 4.00 4.00 4.00 2.00 3.72 3.50 1.53
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - 7.92 18
Noncurrent Employee Benefit Liabilities		 0.00 0.03 0.03 0.03 0.03 0.04 0.04 0.04
Other Noncurrent Operating Liabilities		 0.46 0.35 0.31 0.26 0.12 0.65 0.59 0.49
Commitments & Contingencies		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 148 166 176 156 140 154 202 238
Total Preferred & Common Equity		 149 167 177 156 141 155 203 238
Total Common Equity		 149 167 177 156 141 155 203 238
Common Stock		 320 323 324 323 325 325 326 323
Retained Earnings		 -171 -156 -147 -166 -184 -171 -123 -85

Annual Metrics And Ratios for Oramed Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oramed Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 11,550,846.00 13,136,658.00 13,320,962.00 17,362,615.00 17,383,359.00 23,526,812.00 32,514,145.00 39,114,736.00 40,338,979.00 40,312,069.00 40,312,069.00
DEI Adjusted Shares Outstanding		 11,550,846.00 13,136,658.00 13,320,962.00 17,362,615.00 17,383,359.00 23,526,812.00 32,514,145.00 39,114,736.00 40,338,979.00 40,312,069.00 40,312,069.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.63 -0.83 -0.79 -0.73 -0.83 -0.49 -0.68 -0.93 0.12 -0.47 1.59
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 283.15% -0.29% 10.37% 0.26% -0.26% -68.48% 90.96% -100.00% 0.00%
EBITDA Growth		 -25.07% -35.60% -7.60% -25.59% -3.89% 13.19% -98.08% -55.69% 119.47% -303.17% 607.23%
EBIT Growth		 -25.01% -35.58% -7.60% -25.59% -3.90% 13.19% -98.60% -55.44% 118.92% -311.47% 599.93%
NOPAT Growth		 -25.01% -35.58% -7.60% -25.59% -8.16% 19.64% -106.03% -67.60% 44.51% 43.26% -43.33%
Net Income Growth		 -26.97% -51.60% 4.41% -21.44% -12.79% 19.81% -99.71% -64.27% 128.10% -280.00% 435.11%
EPS Growth		 8.06% 29.85% 0.00% 0.00% 0.00% -31.71% 39.29% -220.51% 114.89% -442.86% 412.50%
Operating Cash Flow Growth		 -21.58% 194.12% -225.26% -151.36% 11.71% 3.86% -70.27% -31.81% 63.12% 18.29% -8.71%
Free Cash Flow Firm Growth		 113.03% -291.16% 246.36% -428.43% 22.00% 73.26% -2,505.03% 73.07% 91.35% 1,401.01% -38.72%
Invested Capital Growth		 -41.28% -25.69% -176.41% 186.76% 112.95% -35.43% 1,333.50% 1.77% -12.62% -47.18% -70.00%
Revenue Q/Q Growth		 0.00% 1,786.84% -2.42% -0.04% 2.43% 0.00% 0.00% -68.48% 95.32% 100.00% 0.00%
EBITDA Q/Q Growth		 30.77% -2,197.69% 47.66% -2.24% 8.96% -10.09% -12.42% -3.05% 134.10% -257.60% 35.05%
EBIT Q/Q Growth		 30.77% -2,211.81% 47.65% -2.24% 8.95% -10.07% -12.41% -3.07% 132.94% -263.36% 35.12%
NOPAT Q/Q Growth		 30.77% -1,578.27% 47.65% -2.24% 33.65% -6.06% -12.37% -11.10% -4.14% 31.51% -25.41%
Net Income Q/Q Growth		 11.39% -153.33% 36.62% -1.84% -2,733.95% 0.00% 0.00% -9.43% 162.64% -292.63% 45.99%
EPS Q/Q Growth		 189.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -536.36% 51.52%
Operating Cash Flow Q/Q Growth		 -4.81% 246.52% -293.08% -21.56% 9.64% 6.11% -29.49% -2.87% 39.22% -6.23% 13.64%
Free Cash Flow Firm Q/Q Growth		 129.96% -442.55% 323.70% -249.21% 18.61% 74.52% -17,711.50% 78.46% 85.73% -49.40% -28.65%
Invested Capital Q/Q Growth		 -11.35% -40.46% -480.32% 393.45% 327.63% -39.13% 3,867.49% -6.97% -20.96% 37.76% 418.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 92.39% 103.51% 96.67% 100.00% 100.00% 100.00% 100.00% 0.00% 0.65%
EBITDA Margin		 0.00% -1,561.00% -438.36% -552.10% -519.68% -449.96% -893.60% -4,413.85% 449.97% 0.00% 3,772.25%
Operating Margin		 0.00% -1,561.62% -438.56% -552.35% -541.29% -433.84% -896.15% -4,765.02% -969.21% 0.00% -754.40%
EBIT Margin		 0.00% -1,561.62% -438.56% -552.35% -519.98% -450.22% -896.45% -4,420.66% 437.92% 0.00% 3,766.20%
Profit (Net Income) Margin		 0.00% -1,710.45% -426.71% -519.68% -531.08% -424.76% -850.50% -4,432.39% 652.30% 0.00% 3,200.80%
Tax Burden Percent		 99.99% 113.86% 103.97% 100.00% 102.13% 100.00% 100.00% 100.27% 208.59% 119.99% 84.99%
Interest Burden Percent		 97.97% 96.19% 93.58% 94.09% 100.00% 94.34% 94.87% 100.00% 71.41% 105.66% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.01%
Return on Invested Capital (ROIC)		 0.00% -76.21% -815.54% 0.00% -125.94% -90.37% -30.95% -27.50% -16.14% 0.00% -41.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -51.96% -802.05% 0.00% -101.92% -71.11% -17.53% -10.67% -60.60% 0.00% -95.39%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 33.23% 769.40% 0.00% 69.10% 46.33% 7.90% 3.73% 22.90% 0.00% 78.10%
Return on Equity (ROE)		 -31.70% -42.98% -46.14% -50.55% -56.85% -44.04% -23.05% -23.77% 6.76% -12.39% 37.10%
Cash Return on Invested Capital (CROIC)		 15.77% -46.74% 0.00% -397.46% -198.13% -47.32% -204.86% -29.25% -2.68% 48.90% 66.69%
Operating Return on Assets (OROA)		 0.00% -28.94% -26.42% -31.42% -34.26% -30.77% -21.79% -22.19% 3.73% 0.00% 39.01%
Return on Assets (ROA)		 0.00% -31.70% -25.70% -29.56% -34.99% -29.03% -20.67% -22.25% 5.55% 0.00% 33.16%
Return on Common Equity (ROCE)		 -31.70% -42.98% -46.14% -50.55% -56.85% -44.04% -23.03% -23.81% 6.79% -12.47% 37.20%
Return on Equity Simple (ROE_SIMPLE)		 -29.13% -41.86% -54.48% -40.91% -74.02% -35.01% -13.81% -24.88% 6.48% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.17 -7.01 -7.54 -9.47 -10 -8.23 -17 -28 -16 -8.95 -13
NOPAT Margin		 0.00% -1,093.14% -306.99% -386.64% -378.90% -303.69% -627.31% -3,335.52% -969.21% 0.00% -641.15%
Net Nonoperating Expense Percent (NNEP)		 -24.13% -24.25% -13.49% -12.74% -24.03% -19.27% -13.42% -16.83% 44.45% -12.02% 54.39%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -7.36% -6.14% -6.40%
Cost of Revenue to Revenue		 0.00% 0.00% 7.61% -3.51% 3.33% 0.00% 0.00% 0.00% 0.00% 0.00% 99.35%
SG&A Expenses to Revenue		 0.00% 382.53% 112.34% 166.72% 137.70% 156.16% 219.64% 1,621.01% 517.82% 0.00% 436.00%
R&D to Revenue		 0.00% 1,202.65% 418.61% 489.14% 500.26% 377.68% 776.51% 3,244.01% 551.38% 0.00% 319.05%
Operating Expenses to Revenue		 0.00% 1,661.62% 530.94% 655.86% 637.96% 533.84% 996.15% 4,865.02% 1,069.21% 0.00% 755.05%
Earnings before Interest and Taxes (EBIT)		 -7.38 -10 -11 -14 -14 -12 -24 -38 7.13 -15 75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.38 -10 -11 -14 -14 -12 -24 -38 7.32 -15 75
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.61 3.62 5.99 2.76 2.98 2.50 3.84 3.10 0.57 0.62 0.00
Price to Tangible Book Value (P/TBV)		 2.61 3.62 5.99 2.76 2.98 2.50 3.84 3.10 0.57 0.62 0.00
Price to Revenue (P/Rev)		 0.00 147.76 46.92 35.09 21.35 30.30 236.73 552.29 57.27 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20.04 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.99% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.80 9.74 0.00 11.55 4.46 7.89 5.62 4.06 0.22 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 119.13 36.64 24.51 18.27 20.80 213.05 496.47 12.57 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.79 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.87 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 16.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 22.53 0.00 14.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.32 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.38 -0.64 -0.96 -1.02 -0.68 -0.65 -0.45 -0.35 -0.38 -0.55 -0.82
Leverage Ratio		 1.06 1.36 1.80 1.71 1.62 1.52 1.12 1.07 1.22 1.22 1.12
Compound Leverage Factor		 1.03 1.30 1.68 1.61 1.62 1.43 1.06 1.07 0.87 1.29 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 17.63% 0.00% 0.00% 23.96% 0.23% 0.33%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.23% 0.00% 0.00% 23.96% 0.23% 0.33%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 17.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.09% -0.43% -0.43% -0.63% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 82.37% 99.91% 100.43% 76.47% 100.40% 99.67%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.58 0.00 0.00 7.01 -0.02 0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 2.11 0.00 1.25 -9.81 6.54 -2.60
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.57 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.86 0.00 0.00 -3.26 -0.04 -0.05
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 3.13 0.00 1.65 4.55 10.87 15.30
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.84 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 23.46 1.93 1.12 0.90 -1.30 1.41 33.77 25.87 0.68 4.64 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.08% -0.16% -0.50% -0.60% -0.27%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.67 8.62 3.93 6.82 6.28 8.93 20.08 27.34 3.06 25.19 6.98
Quick Ratio		 3.56 1.87 1.32 2.11 1.32 6.36 4.78 7.69 1.25 15.24 6.02
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2.25 -4.30 6.29 -21 -16 -4.31 -112 -30 -2.62 34 21
Operating Cash Flow to CapEx		 -494,600.00% 51,722.22% -83,300.00% -293,140.00% -86,266.67% -15,170.73% -5,648.27% -5,914.83% -4,053.15% -46,733.33% -101,611.11%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.28 39.90 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.05 -9.86 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.18 -9.88 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.06 0.06 0.07 0.07 0.02 0.01 0.01 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 47.48 144.47 139.94 131.85 44.07 11.10 1.42 1.93 0.00 3.12
Accounts Payable Turnover		 0.00 0.00 0.09 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.35
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 4,074.53 0.00 9,548.81 0.00 0.00 0.00 0.00 0.00 1,041.64
Cash Conversion Cycle (CCC)		 0.00 0.00 -4,074.53 0.00 -9,548.81 0.00 0.00 0.00 0.00 0.00 -1,041.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 7.84 -5.99 5.20 11 7.15 102 104 91 48 14
Invested Capital Turnover		 0.00 0.07 2.66 -6.18 0.33 0.30 0.05 0.01 0.02 0.00 0.06
Increase / (Decrease) in Invested Capital		 -7.42 -2.71 -14 11 5.87 -3.92 95 1.81 -13 -43 -34
Enterprise Value (EV)		 51 76 90 60 49 56 576 423 20 -7.20 0.00
Market Capitalization		 65 95 115 86 58 82 640 471 93 91 0.00
Book Value per Share		 $2.15 $1.99 $1.44 $1.79 $1.12 $1.40 $5.12 $3.88 $4.06 $3.63 $4.82
Tangible Book Value per Share		 $2.15 $1.99 $1.44 $1.79 $1.12 $1.40 $5.12 $3.88 $4.06 $3.63 $4.82
Total Capital		 25 26 19 31 19 40 167 151 214 146 200
Total Debt		 0.00 0.00 0.00 0.00 0.00 7.04 0.00 0.00 51 0.33 0.65
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 6.95 0.00 0.00 0.00 0.00 0.00
Net Debt		 -14 -18 -25 -26 -8.33 -26 -64 -47 -72 -97 -196
Capital Expenditures (CapEx)		 0.00 0.01 0.01 0.01 0.02 0.08 0.38 0.47 0.25 0.02 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 21 8.29 17 21 7.23 105 107 94 51 -0.08
Debt-free Net Working Capital (DFNWC)		 16 28 15 26 28 36 141 151 161 138 115
Net Working Capital (NWC)		 16 28 15 26 28 36 141 151 109 138 114
Net Nonoperating Expense (NNE)		 2.06 3.96 2.94 3.26 4.11 3.28 6.03 9.35 -26 10 -77
Net Nonoperating Obligations (NNO)		 -14 -18 -25 -26 -8.33 -26 -64 -47 -72 -97 -185
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.01 0.01 0.01 0.01 0.08 0.06 0.20 0.19 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 3,249.77% 337.42% 689.91% 776.40% 266.61% 3,898.11% 12,577.11% 5,773.82% 0.00% -3.90%
Debt-free Net Working Capital to Revenue		 0.00% 4,307.18% 616.12% 1,081.42% 1,036.48% 1,330.81% 5,200.48% 17,765.73% 9,877.57% 0.00% 5,741.85%
Net Working Capital to Revenue		 0.00% 4,307.18% 616.12% 1,081.42% 1,036.48% 1,327.49% 5,200.48% 17,765.61% 6,722.19% 0.00% 5,709.25%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.67 $0.87 $0.79 $0.86 $0.00 $0.56 $0.78 $0.94 $0.14 ($0.48) $1.53
Adjusted Weighted Average Basic Shares Outstanding		 11.60M 13.26M 14.31M 17.38M 17.40M 23.68M 38.09M 39.00M 40.32M 40.83M 41.40M
Adjusted Diluted Earnings per Share		 $0.67 $0.87 $0.79 $0.86 $0.00 $0.56 $0.78 $0.00 $0.14 ($0.48) $1.50
Adjusted Weighted Average Diluted Shares Outstanding		 11.60M 13.26M 14.31M 17.38M 17.40M 23.68M 38.09M 39.78M 40.57M 40.83M 42.42M
Adjusted Basic & Diluted Earnings per Share		 $0.67 $0.87 $0.79 $0.86 $0.00 $0.56 $0.78 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 28.47M 39.78M 40.52M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -5.17 -7.01 -7.54 -9.47 -10 -8.23 -17 -28 -11 -8.95 -13
Normalized NOPAT Margin		 0.00% -1,093.14% -306.99% -386.64% -378.90% -303.69% -627.31% -3,335.52% -678.45% 0.00% -641.15%
Pre Tax Income Margin		 0.00% -1,502.18% -410.42% -519.68% -519.98% -424.76% -850.50% -4,420.66% 312.72% 0.00% 3,766.20%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.50 -17.66 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.74 -10.49 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.37 -17.68 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.87 -10.51 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.00% 7.41%

Quarterly Metrics And Ratios for Oramed Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oramed Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 40,275,688.00 40,338,979.00 40,338,979.00 40,628,924.00 40,769,027.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00
DEI Adjusted Shares Outstanding		 40,275,688.00 40,338,979.00 40,338,979.00 40,628,924.00 40,769,027.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.08 0.31 0.04 0.23 -0.48 -0.25 -0.19 0.33 1.20 0.25 0.95
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.79% 67.86% -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 66.32% 249.75% 161.05% 984.46% -667.76% -166.98% -422.09% 18.03% 422.27% 200.77% 803.90%
EBIT Growth		 65.64% 248.94% 158.88% 945.32% -653.01% -167.44% -431.98% 18.34% 421.20% 200.14% 800.48%
NOPAT Growth		 64.67% 43.14% 18.75% -0.33% -6.78% 35.09% -6.35% 5.61% 8.64% -130.27% 9.99%
Net Income Growth		 54.72% 315.44% 142.48% 800.99% -498.11% -154.19% -598.17% 44.07% 346.35% 198.14% 601.31%
EPS Growth		 0.00% 0.00% 150.00% 833.33% -500.00% -178.79% -575.00% 40.91% 335.42% 196.15% 578.95%
Operating Cash Flow Growth		 69.03% 82.41% 73.40% 178.82% -923.20% -34.77% -138.41% -270.28% 77.12% 75.61% 17.16%
Free Cash Flow Firm Growth		 95.68% 207.49% 268.59% 321.40% 1,600.12% 336.23% 11.95% -112.21% -52.04% -31.09% -17.49%
Invested Capital Growth		 2.84% -12.62% -36.94% -83.61% -69.69% -47.18% -65.35% 49.86% -112.97% -70.00% -156.50%
Revenue Q/Q Growth		 -1.63% -156.71% 100.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -90.64% 705.66% -85.01% 411.14% -265.49% 47.16% 27.93% 287.31% 351.85% -83.48% 403.41%
EBIT Q/Q Growth		 -87.20% 690.20% -85.35% 422.06% -266.76% 47.14% 27.85% 286.09% 352.65% -83.52% 404.64%
NOPAT Q/Q Growth		 23.69% -91.45% 23.60% 10.12% 18.78% -16.38% -25.17% 20.23% 21.39% -193.34% 51.07%
Net Income Q/Q Growth		 -150.11% 673.11% -91.85% 500.00% -313.41% 48.08% 25.07% 273.51% 264.92% -79.32% 282.76%
EPS Q/Q Growth		 -166.67% 512.50% -87.88% 450.00% -318.18% 45.83% 26.92% 263.16% 264.52% -77.88% 264.00%
Operating Cash Flow Q/Q Growth		 73.65% -104.32% -4.09% 240.65% -442.05% 73.09% -84.14% -0.45% 54.03% 71.32% -525.54%
Free Cash Flow Firm Q/Q Growth		 89.87% 278.04% 350.15% 172.80% -31.39% -48.23% 15.52% -129.75% 369.53% -25.60% 38.31%
Invested Capital Q/Q Growth		 -17.34% -20.96% -16.18% -70.07% 52.85% 37.76% -45.01% 29.43% -113.23% 418.61% -203.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.65% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -362.59% 0.00% 0.00% 0.00% 0.00% 0.00% -351.40% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -436.35% 0.00% 0.00% 0.00% 0.00% 0.00% -225.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -370.74% 0.00% 0.00% 0.00% 0.00% 0.00% -352.90% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -495.32% 0.00% 0.00% 0.00% 0.00% 0.00% -382.10% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 141.55% 100.00% 84.92% 106.12% 104.25% 108.27% 100.96% 81.39% 102.16% 77.49%
Interest Burden Percent		 133.60% 91.65% 72.15% 97.65% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 15.08% 0.00% 0.00% 0.00% -0.96% 18.61% -2.16% 22.51%
Return on Invested Capital (ROIC)		 -2.24% 0.00% 0.00% 0.00% 0.00% 0.00% -6.13% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 1.16% 0.00% 0.00% 0.00% 0.00% 0.00% -1.70% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -0.29% 0.00% 0.00% 0.00% 0.00% 0.00% 1.13% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -2.52% 0.00% 0.00% 0.00% 6.53% -12.39% -5.00% 0.00% 0.00% 0.00% 58.16%
Cash Return on Invested Capital (CROIC)		 -16.13% -2.68% 31.60% 127.82% 89.57% 48.90% 77.57% -73.44% 0.00% 66.69% 0.00%
Operating Return on Assets (OROA)		 -1.56% 0.00% 0.00% 0.00% 0.00% 0.00% -4.02% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -2.09% 0.00% 0.00% 0.00% 0.00% 0.00% -4.35% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -2.54% 0.00% 0.00% 0.00% 6.57% -12.47% -5.03% 0.00% 0.00% 0.00% 58.30%
Return on Equity Simple (ROE_SIMPLE)		 -11.36% 0.00% 9.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.03 -3.88 -2.96 -2.66 -2.16 -2.52 -3.15 -2.51 -1.98 -5.79 -2.84
NOPAT Margin		 -305.44% 0.00% 0.00% 0.00% 0.00% 0.00% -157.50% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.40% 38.24% 7.59% 14.42% -22.76% -9.09% -4.43% 11.57% 30.76% 11.19% 22.44%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.81% -1.50% -1.51% -1.39% -1.73% -2.25% -1.64% -0.98% -2.89% -1.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 99.35% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 392.01% 0.00% 0.00% 0.00% 0.00% 0.00% 115.35% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 144.34% 0.00% 0.00% 0.00% 0.00% 0.00% 110.30% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 536.35% 0.00% 0.00% 0.00% 0.00% 0.00% 225.65% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.46 15 2.13 11 -19 -9.78 -7.06 13 59 9.80 49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.40 15 2.18 11 -18 -9.75 -7.03 13 59 9.83 49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.70 0.57 0.71 0.59 0.64 0.62 0.57 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.70 0.57 0.71 0.59 0.64 0.62 0.57 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 126.19 57.27 122.57 363.82 0.00 0.00 40.21 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 20.04 12.29 5.22 27.70 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.35%
Earnings Yield		 0.00% 4.99% 8.13% 19.14% 3.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.62 0.22 0.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 85.52 12.57 28.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 2.79 2.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 2.87 2.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.51 0.32 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.25 -0.38 -0.38 -0.50 -0.51 -0.55 -0.66 -0.83 -0.92 -0.82 -0.97
Leverage Ratio		 1.31 1.22 1.15 1.04 1.30 1.22 1.15 1.05 1.08 1.12 1.10
Compound Leverage Factor		 1.75 1.12 0.83 1.02 1.30 1.22 1.15 1.05 1.08 1.12 1.10
Debt to Total Capital		 33.71% 23.96% 16.20% 0.00% 0.02% 0.23% 0.03% 0.02% 0.00% 0.33% 0.00%
Short-Term Debt to Total Capital		 33.71% 23.96% 16.20% 0.00% 0.02% 0.23% 0.03% 0.02% 0.00% 0.33% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.40% -0.43% -0.46% -0.52% -0.59% -0.63% -0.66% -0.62% -0.47% 0.00% 0.00%
Common Equity to Total Capital		 66.70% 76.47% 84.27% 100.52% 100.57% 100.40% 100.63% 100.59% 100.47% 99.67% 100.00%
Debt to EBITDA		 -3.51 7.01 2.45 0.00 0.00 -0.02 0.00 0.00 0.00 0.01 0.00
Net Debt to EBITDA		 1.54 -9.81 -6.83 0.00 -12.78 6.54 4.71 5.41 -3.70 -2.60 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -4.98 -3.26 -2.37 0.00 0.00 -0.04 0.00 0.00 0.00 -0.05 0.00
Net Debt to NOPAT		 2.18 4.55 6.61 0.00 9.23 10.87 11.32 12.47 20.23 15.30 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.20 0.79 1.68 7.82 5.46 4.76 5.44 0.00 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 -0.52% 0.00% 0.00% 0.00% -0.60% -0.60% -0.60% 0.00% 0.00% 0.00% -0.24%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.25 3.06 5.28 41.06 27.08 25.19 23.94 26.81 22.25 6.98 6.45
Quick Ratio		 0.70 1.25 2.87 40.44 18.88 15.24 18.93 20.33 21.35 6.02 5.18
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.21 9.28 42 114 78 40 47 -14 37 28 39
Operating Cash Flow to CapEx		 -2,168.75% -47,266.67% -73,800.00% 0.00% -142,020.00% -17,372.73% -117,300.00% -88,375.00% 0.00% -23,300.00% -58,300.00%
Free Cash Flow to Firm to Interest Expense		 -6.31 7.66 70.53 436.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -0.84 -1.17 -2.49 7.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -0.88 -1.17 -2.50 7.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.14 1.93 1.07 0.34 0.00 0.00 2.68 2.84 3.00 3.12 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.61 0.70 0.40 0.35 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 600.86 518.20 905.24 1,041.64 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -600.86 -518.20 -905.24 -1,041.64 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 115 91 76 23 35 48 26 34 -4.53 14 -15
Invested Capital Turnover		 0.01 0.02 0.01 0.00 0.00 0.00 0.04 0.07 0.13 0.06 0.00
Increase / (Decrease) in Invested Capital		 3.19 -13 -45 -117 -80 -43 -50 11 -39 -34 -41
Enterprise Value (EV)		 71 20 28 -50 -22 -7.20 -34 0.00 0.00 0.00 0.00
Market Capitalization		 105 93 118 104 99 91 80 0.00 0.00 0.00 0.00
Book Value per Share		 $3.70 $4.06 $4.08 $4.36 $3.84 $3.63 $3.42 $3.70 $4.87 $4.82 $5.84
Tangible Book Value per Share		 $3.70 $4.06 $4.08 $4.36 $3.84 $3.63 $3.42 $3.70 $4.87 $4.82 $5.84
Total Capital		 224 214 198 176 156 146 140 154 202 200 238
Total Debt		 75 51 32 0.00 0.04 0.33 0.04 0.03 0.00 0.65 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -33 -72 -89 -153 -121 -97 -113 -119 -207 -196 -254
Capital Expenditures (CapEx)		 0.03 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 118 94 79 -1.42 38 51 22 20 -0.65 -0.08 2.84
Debt-free Net Working Capital (DFNWC)		 173 161 176 150 138 138 126 95 130 115 58
Net Working Capital (NWC)		 98 109 144 150 138 138 126 95 130 114 58
Net Nonoperating Expense (NNE)		 1.26 -23 -4.50 -12 17 7.68 4.49 -16 -50 -16 -41
Net Nonoperating Obligations (NNO)		 -33 -72 -89 -153 -121 -97 -113 -119 -207 -185 -253
Total Depreciation and Amortization (D&A)		 0.05 0.05 0.06 0.05 0.05 0.03 0.03 0.03 0.03 0.03 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 14,167.11% 5,773.82% 8,248.18% -495.47% 0.00% 0.00% 1,103.85% 1,014.60% -32.50% -3.90% 0.00%
Debt-free Net Working Capital to Revenue		 20,755.46% 9,877.57% 18,269.93% 52,103.48% 0.00% 0.00% 6,301.00% 4,768.35% 6,499.95% 5,741.85% 0.00%
Net Working Capital to Revenue		 11,708.28% 6,722.19% 14,936.42% 52,103.48% 0.00% 0.00% 6,299.20% 4,766.65% 6,499.90% 5,709.25% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.08 $0.33 $0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.32 $1.16 $0.24 $0.94
Adjusted Weighted Average Basic Shares Outstanding		 40.45M 40.32M 40.84M 40.96M 40.90M 40.85M 41.23M 41.74M 41.76M 41.40M 40.77M
Adjusted Diluted Earnings per Share		 $0.00 $0.33 $0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.31 $1.13 $0.25 $0.91
Adjusted Weighted Average Diluted Shares Outstanding		 40.34M 40.57M 41.56M 41.59M 40.90M 40.85M 41.23M 42.61M 42.77M 42.42M 41.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.34M 40.52M 40.63M 40.77M 40.31M 0.00 40.85M 41.00M 39.80M 0.00 40.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.03 -2.71 -2.07 -2.66 -2.16 -2.52 -3.15 -1.74 -1.98 -3.97 -2.84
Normalized NOPAT Margin		 -305.44% 0.00% 0.00% 0.00% 0.00% 0.00% -157.50% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -495.32% 0.00% 0.00% 0.00% 0.00% 0.00% -352.90% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2.98 11.98 3.59 42.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -2.45 -3.20 -5.00 -10.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -3.01 11.98 3.59 42.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2.49 -3.20 -5.01 -10.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 13.02% -13.00% 0.00% -11.81% 4.39% 7.41% 0.00%

Financials Breakdown Chart

Oramed Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Oramed Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Oramed Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $64.02 million in 2025, falling from -$7.23 million in 2015. The previous period was -$19.10 million in 2024. View Oramed Pharmaceuticals' forecast to see where analysts expect Oramed Pharmaceuticals to go next.

Oramed Pharmaceuticals' total operating income in 2025 was -$15.09 million, based on the following breakdown:
  • Total Gross Profit: $13 thousand
  • Total Operating Expenses: $15.10 million

Over the last 10 years, Oramed Pharmaceuticals' total revenue changed from $0.00 in 2015 to $2 million in 2025, a change of 200,000,000.0%.

Oramed Pharmaceuticals' total liabilities were at $31.12 million at the end of 2025, a 213.4% increase from 2024, and a 1,939.3% increase since 2015.

In the past 10 years, Oramed Pharmaceuticals' cash and equivalents has ranged from $3.21 million in 2015 to $54.42 million in 2024, and is currently $45.95 million as of their latest financial filing in 2025.

Over the last 10 years, Oramed Pharmaceuticals' book value per share changed from 2.15 in 2015 to 4.82 in 2025, a change of 124.4%.


Related Companies

Financial statements for NASDAQ:ORMP last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Elon’s New Currency (BUY NOW)
Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...
InvestorPlace | Sponsoredtc pixel
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel